The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Mondanelli, Giada ^a   Albini, Elisa ^a   Pallotta, Maria T ^a   Volpi, Claudia ^a   Chatenoud, Lucienne ^b   Kuhn, Chantal ^c   Fallarino, Francesca ^a   Matino, Davide ^a   Belladonna, Maria L ^a   Bianchi, Roberta ^a   Vacca, Carmine ^a   Bicciato, Silvio ^d   Boon, Louis ^e   Ricci, Giovanni ^a   Grohmann, Ursula ^a   Puccetti, Paolo ^a   Orabona, Ciriana ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b INSERM   (France)

^c VL37 Inc   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e BIOCEROS   (Netherlands)

Author keywords

Anti CD3 antibody; Autoimmune diabetes; Dendritic cells; Immune regulation; Indoleamine 2,3 dioxygenase 1 enzyme; Proteasome; Tryptophan metabolism

Indexed keywords

BORTEZOMIB; CD3 ANTIBODY; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; KYNURENINE; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN I; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL INFILTRATION; CONTROLLED STUDY; CYTOFLUOROMETRY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOREGULATION; MOUSE; NONHUMAN; PERITONEUM CELL; PHENOTYPE; PROTEIN EXPRESSION; SKIN TEST; WESTERN BLOTTING;

EID: 85018371367     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00428     Document Type: Article

References (48)

1. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol (2011) 29:163-83. doi: 10.1146/annurev-immunol-031210-101345
2. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 5(12):1219-26. doi:10.1038/ni1141
3. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 8(8):594-606. doi:10.1038/nri2358
4. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med (2004) 200(8):1051-62. doi:10.1084/jem.20040942
5. Lippens C, Duraes FV, Dubrot J, Brighouse D, Lacroix M, Irla M, et al. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun (2016) 75:39-49. doi:10.1016/j.jaut.2016.07.004
6. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12(9):870-8. doi:10.1038/ni.2077
7. Pallotta MT, Orabona C, Bianchi R, Vacca C, Fallarino F, Belladonna ML, et al. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes. J Cell Mol Med (2014) 18(10):2082-91. doi:10.1111/jcmm.12360
8. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 105(52):20828-33. doi:10.1073/pnas.0810278105
9. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med (2003) 198(1):153-60. doi:10.1084/jem.20030633
10. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol (2009) 183(10):6303-12. doi:10.4049/jimmunol.0901577
11. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest (1991) 87(2):739-42. doi:10.1172/JCI115055
12. Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol (2015) 33(4 Suppl 92):S74-9
13. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol (2010) 185(1):634-41. doi:10.4049/jimmunol.0903182
14. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 64(2):493-503. doi:10.1002/art.33333
15. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 15(7):781-7. doi:10.1038/nm.1978
16. Belogurov A Jr, Kuzina E, Kudriaeva A, Kononikhin A, Kovalchuk S, Surina Y, et al. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J (2015) 29(5):1901-13. doi:10.1096/fj.14-259333
17. Sula Karreci E, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A (2016) 113(52):E8425-32. doi:10.1073/pnas.1618548114
18. Fierabracci A. Proteasome inhibitors: a new perspective for treating autoimmune diseases. Curr Drug Targets (2012) 13(13):1665-75. doi:10.2174/138945012803530053
19. Wang Y, Liang Y, Zhang Y, Wu D, Liu H. Bortezomib inhibits bone marrow-derived dendritic cells. Int J Clin Exp Pathol (2015) 8(5):4857-62
20. Albini E, Rosini V, Gargaro M, Mondanelli G, Belladonna ML, Pallotta MT, et al. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J Cell Mol Med (2017) 21:165-76. doi:10.1111/jcmm.12954
21. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 62(17):4996-5000
22. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 158(6):2947-54
23. Ioannou M, Alissafi T, Boon L, Boumpas D, Verginis P. In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells. J Immunol (2013) 190(6):2631-40. doi:10.4049/jimmunol.1201897
24. Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med (2009) 206(11):2511-26. doi:10.1084/jem.20090134
25. Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy (2015) 7(9):1011-22. doi:10.2217/imt.15.66
26. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov (2003) 2(8):611-2. doi:10.1038/nrd1159
27. Wheat W, Kupfer R, Gutches DG, Rayat GR, Beilke J, Scheinman RI, et al. Increased NF-kappa B activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur J Immunol (2004) 34(5):1395-404. doi:10.1002/eji.200324490
28. Weaver DJ Jr, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS Jr, Tisch R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol (2001) 167(3):1461-8. doi:10.4049/jimmunol.167.3.1461
29. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes (2002) 51(2):356-65. doi:10.2337/diabetes.51.2.356
30. Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H, et al. Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes (2007) 56(6):1686-93. doi:10.2337/db06-1727
31. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes (2009) 58(1):138-45. doi:10.2337/db08-0964
32. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 9(9):1202-8. doi:10.1038/nm924
33. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 104(15):6335-40. doi:10.1073/pnas.0701171104
34. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 352(25):2598-608. doi:10.1056/NEJMoa043980
35. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther (2015) 17:17. doi:10.1186/s13075-015-0529-1
36. Kisselev AF, Groettrup M. Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol (2014) 23:16-22. doi:10.1016/j.cbpa.2014.08.012
37. Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P, Paraskeva A, Bougiouklis D, et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum (2010) 62(11):3277-88. doi:10.1002/art.27690
38. Grohmann U, Fallarino F, Bianchi R, Vacca C, Orabona C, Belladonna ML, et al. Tryptophan catabolism in nonobese diabetic mice. Adv Exp Med Biol (2003) 527:47-54. doi:10.1007/978-1-4615-0135-0_5
39. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 18:834-42. doi:10.2119/molmed.2012.00029
40. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol (2012) 42(8):1932-7. doi:10.1002/eji.201242572
41. Grohmann U, Puccetti P. The coevolution of IDO1 and AhR in the emergence of regulatory T-cells in mammals. Front Immunol (2015) 6:58. doi:10.3389/fimmu.2015.00058
42. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 511(7508):184-90. doi:10.1038/nature13323
43. Fallarino F, Romani L, Puccetti P. AhR: far more than an environmental sensor. Cell Cycle (2014) 13(17):2645-6. doi:10.4161/15384101.2014.954219
44. Morel PA. Dendritic cell subsets in type 1 diabetes: friend or foe? Front Immunol (2013) 4:415. doi:10.3389/fimmu.2013.00415
45. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol (2013) 149(3):268-78. doi:10.1016/j.clim.2013.05.001
46. Vudattu NK, Herold KC. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther (2014) 14(3):377-85. doi:10.1517/14712598.2014.881797
47. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 378(9790):487-97. doi:10.1016/S0140-6736(11)60931-8
48. Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy (2016) 8(8):889-906. doi:10.2217/imt-2016-0049